EAM
TNGX icon

Exos Asset Management’s Tango Therapeutics TNGX Stock Holding History

Exos Asset Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,100
Closed -$13K – 457
2020
Q4 		$13K Buy
+1,100
New +$11.6K 0.02% 217

Other funds holding TNGX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Exos Asset Management's TNGX Position: Q1 2021 in Review

Exos Asset Management sold out of Tango Therapeutics (TNGX) in Q1 2021, closing a stake of 1,100 shares — an estimated $13K sold.

Exos Asset Management first reported a position in TNGX in Q4 2020 and held it in 1 quarter. The position peaked at $13K in Q4 2020. 36 funds tracked by Wall St. Rank hold TNGX as of Q1 2021.

  • Exos Asset Management reported no remaining Tango Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Exos Asset Management sold 1,100 Tango Therapeutics shares in Q1 2021, an estimated $13K.
  • Exos Asset Management first reported a position in Tango Therapeutics in Q4 2020 and held it in 1 quarter.
  • Exos Asset Management's Tango Therapeutics position peaked at $13K in Q4 2020.
  • 36 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2021.

Based on Exos Asset Management's 13F filing for Q1 2021, filed 5 May 2021.